Skip to main content
. 2021 Jun 7;1(7):998–1013. doi: 10.1021/jacsau.1c00160

Figure 4.

Figure 4

In vitro study of the antineuroinflammation and pro-neurogenesis effects of DNIC-1. Cell viability assay of the (a) BV-2 and (b) N2A cells treated with different concentrations of DNIC-1 for 24 h. ***P < 0.001 compared to the group without treatment of DNIC-1. (c) Effect of DNIC-1 on the production and secretion of TNF-α in LPS-activated BV-2. Data are presented as means ± SEM. ###P < 0.001 compared with the untreated control group. ***P < 0.001 compared with the group treated with LPS alone. (d) Concentration of nitric oxide in the supernatant culture media for BV-2 cells without (black) or with (gray) the treatment of 5 μM of DNIC-1. Concentration of nitric oxide in the medium with the treatment of DNIC-1 (5 μM) is shown in white. **P < 0.01. In comparison with free DNIC-1, a significant decrease of nitric oxide in the supernatant culture media in the presence of BV-2 indicates the cellular uptake of DNIC-1 and nitric oxide.